Tyrosine kinase inhibitors (TKIs) targeting the BCR::ABL1 oncoprotein are the standard of care for chronic myeloid leukemia (CML) [1, 2]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.